• Joshua D Mezrich, Sarwa Darwish Murad, William C Chapman, W Ray Kim, Jason J Schwartz, Denise M Harnois, David D Douglas, Johnny C Hong, James Burton, Jean C Emond, Laura M Kulik, Jean F Botha, Hoonbae Jeon, Charles B Rosen, Gregory J Gores, and Julie K Heimbach.
• William J. von Liebig Transplant Center, Mayo Clinic, Rochester, Minnesota 55905, USA.
• Gastroenterology. 2012 Jul 1; 143 (1): 88-98.e3; quiz e14.

Background & AimsExcellent single-center outcomes of neoadjuvant chemoradiation and liver transplantation for unresectable perihilar cholangiocarcinoma caused the United Network of Organ Sharing to offer a standardized model of end-stage liver disease (MELD) exception for this disease. We analyzed data from multiple centers to determine the effectiveness of this treatment and the appropriateness of the MELD exception.MethodsWe collected and analyzed data from 12 large-volume transplant centers in the United States. These centers met the inclusion criteria of treating 3 or more patients with perihilar cholangiocarcinoma using neoadjuvant therapy, followed by liver transplantation, from 1993 to 2010 (n = 287 total patients). Center-specific protocols and medical charts were reviewed on-site.ResultsThe patients completed external radiation (99%), brachytherapy (75%), radiosensitizing therapy (98%), and/or maintenance chemotherapy (65%). Seventy-one patients dropped out before liver transplantation (rate, 11.5% in 3 months). Intent-to-treat survival rates were 68% and 53%, 2 and 5 years after therapy, respectively; post-transplant, recurrence-free survival rates were 78% and 65%, respectively. Patients outside the United Network of Organ Sharing criteria (those with tumor mass >3 cm, transperitoneal tumor biopsy, or metastatic disease) or with a prior malignancy had significantly shorter survival times (P < .001). There were no differences in outcomes among patients based on differences in surgical staging or brachytherapy. Although most patients came from 1 center (n = 193), the other 11 centers had similar survival times after therapy.ConclusionsPatients with perihilar cholangiocarcinoma who were treated with neoadjuvant therapy followed up by liver transplantation at 12 US centers had a 65% rate of recurrence-free survival after 5 years, showing this therapy to be highly effective. An 11.5% drop-out rate after 3.5 months of therapy indicates the appropriateness of the MELD exception. Rigorous selection is important for the continued success of this treatment.Copyright © 2012 AGA Institute. Published by Elsevier Inc. All rights reserved.

20 keywords...

hide…